Efficacy and safety of weekly carfilzomib (70 mg/m(2)), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies
Por:
Leleu, X, Beksac, M, Chou, T, Dimopoulos, M, Yoon, SS, Prince, HM, Pour, L, Shelekhova, T, Chari, A, Khurana, M, Zhang, JQ, Obreja, M, Qi, M, Oriol, A and Siegel, D
Publicada:
28 ene 2021
Ahead of Print:
1 oct 2020
Resumen:
The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m(2) carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m(2) carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). We analyzed efficacy data from comparable CANDOR and EQUULEUS patients using inverse probability of treatment weighting (IPTW)-adjusted models. These weights were calculated from propensity scores derived to balance prespecified baseline covariates. The side-by-side and adjusted comparisons showed similar efficacy for overall response rates and progression-free survival in the two groups, with a series of sensitivity analyses showing consistent findings. Safety data were generally consistent with the known safety profiles of each individual drug. Once-weekly KdD70 is comparable to twice-weekly KdD56 in terms of efficacy and safety while being a more convenient dosing option.
Filiaciones:
Leleu, X:
CHU, Serv Hematol & Therapie Cellulaire, Poitiers, France
INSERM, Poitiers, France
Beksac, M:
Ankara Univ, Dept Hematol, Ankara, Turkey
Chou, T:
Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan
Dimopoulos, M:
Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Hematol & Med Oncol, Athens, Greece
Yoon, SS:
Seoul Natl Univ, Dept Internal Med, Seoul, South Korea
Prince, HM:
Univ Melbourne, Epworth Healthcare, Melbourne, Vic, Australia
Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
Pour, L:
Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic
Shelekhova, T:
Clin Profess Pathol, Saratov, Russia
Chari, A:
Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
Khurana, M:
Amgen Inc, Oncol, Clin Dev, Thousand Oaks, CA 91320 USA
Zhang, JQ:
Amgen Inc, Global Biostat Sci, Thousand Oaks, CA 91320 USA
Obreja, M:
Amgen Inc, Global Biostat Sci, Thousand Oaks, CA 91320 USA
Qi, M:
Janssen Res & Dev LLC, Hematol & Oncol, Spring House, PA USA
:
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain
Hosp Badalona Germans Trias & Pujol, Josep Carreras Res Leukaemia Inst, Barcelona, Spain
Siegel, D:
Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
hybrid, Green Published
|